202P A phase Ib/II study of OP-1250, an oral complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD) with palbociclib in patients (pts) with advanced or metastatic ER-positive, HER2-negative breast cancer (MBC)
| Autor: | Chan, A., Dinh, P., Day, D., Slancar, M., Ganju, V., McCarthy, N.J., Lombard, J., Faltaos, D., Shilkrut, M., Wilson, R., Murphy, C. |
|---|---|
| Zdroj: | In ESMO Open May 2023 8(1) Supplement 4 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|